Fig. 4.

In vivo antitumor activity of LY2835219 in subcutaneous human tumor xenografts. Tumors were implanted in the rear flank of athymic mice and randomized for treatment when the mean tumor volume reached 150 to 200 mm³. LY2835219 and PD0332991 were administered at the indicated dose and schedule. treatment period is indicated by the horizontal black bar along the X-axis, body weight shown for each experiment is shown in the upper left corner. a effect of 25, 50, or 100 mg/kg of LY2835219 and 100 mg/kg PD0332991 on colo-205 xenografts. b inhibition of cell cycle markers in colo-205 xenografts at the end of treatment with 100 mg/kg LY2835219. c effect of 25, 50, or 100 mg/kg LY2835219 and 50 mg/kg PD0332991 in MV4-11 xenografts. d LY2835219 inhibits tumor growth and is well tolerated in mice bearing colo-205 xenografts when dosed 56 days with 50 mg/kg continuously or intermittently